Pedersen Anders Degn, Rossen Philip, Mehlsen Mimi Yung, Pedersen Christina Gundgaard, Zachariae Robert, von der Maase Hans
Department of Neuropsychology Hammel Neurorehabilitation and Research Center, Aarhus University Hospital, Denmark.
J Int Neuropsychol Soc. 2009 Mar;15(2):296-301. doi: 10.1017/S1355617709090316. Epub 2009 Feb 10.
Cancer patients frequently report cognitive complaints following chemotherapy, but the results from the available studies, mainly of women with breast cancer, are inconsistent. Our aim was to compare cognitive function of men with testicular cancer (TC) who had orchiectomy and chemotherapy (bleomycin, etoposide, cisplatin) with men who had orchiectomy only or orchiectomy and radiotherapy. Thirty-six chemotherapy patients and 36 nonchemotherapy patients were tested 2-7 years after treatment for TC with standardized neuropsychological tests. Chemotherapy and nonchemotherapy patients displayed similar performances on cognitive tests (p values adjusted for multiple comparisons: .63-1.00). Moreover, there was no difference in the proportion of cognitively impaired patients in the chemotherapy group (5.6%) compared to the nonchemotherapy group (8.3%) (chi2 = 0.22, p = .64). Our results are discordant with previous findings indicating cognitive impairment following chemotherapy and suggest that TC patients do not need to fear long-term cognitive consequences following chemotherapy.
癌症患者经常报告化疗后出现认知方面的不适，但现有研究（主要针对乳腺癌女性患者）的结果并不一致。我们的目的是比较接受睾丸切除术和化疗（博来霉素、依托泊苷、顺铂）的睾丸癌（TC）男性患者与仅接受睾丸切除术或接受睾丸切除术及放疗的男性患者的认知功能。对36名接受化疗的患者和36名未接受化疗的患者在接受TC治疗2至7年后进行了标准化神经心理学测试。化疗患者和未化疗患者在认知测试中的表现相似（经多重比较调整后的p值：0.63 - 1.00）。此外，化疗组认知受损患者的比例（5.6%）与未化疗组（8.3%）相比没有差异（卡方 = 0.22，p = 0.64）。我们的结果与先前表明化疗后存在认知障碍的研究结果不一致，并表明睾丸癌患者无需担心化疗后的长期认知后果。
